Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17178006 | 1.00 | P2RX7 (0.35) | P2RX7MAPK1PSEN1 | |
| SCHEMBL17178005 | 1.00 | P2RX7 (0.35) | P2RX7MAPK1PSEN1 | |
| SCHEMBL29989231 | 0.89 | P2RX7 (0.38) | P2RX7MAPK1 | |
| SCHEMBL17162692 | 0.89 | P2RX7 (0.38) | P2RX7MAPK1 | |
| SCHEMBL22668 | 0.83 | P2RX7 (0.33) | P2RX7MAPK1 | |
| SCHEMBL17162572 | 0.81 | DDB1 (0.38) | MAPK1 | |
| SCHEMBL17174481 | 0.81 | DDB1 (0.38) | MAPK1 | |
| SCHEMBL17174477 | 0.81 | DDB1 (0.38) | MAPK1 | |
| SCHEMBL22688357 | 0.80 | P2RX7 (0.35) | P2RX7MAPK1 | |
| SCHEMBL17174472 | 0.80 | P2RX7 (0.42) | P2RX7MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340650-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2017-11-30 | — | — | US | disclosed |
| US-20170334946-A1 | OXOLUPENE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2017-11-23 | — | — | US | disclosed |
| US-9527882-B2 | Triterpenoids with HIV maturation inhibitory activity | ViiV Healthcare UK (No.4) Limited (GB) | 2016-12-27 | — | — | US | disclosed |
| WO-2016077561-A1 | OXOLUPENE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20150291655-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-10-15 | — | — | US | disclosed |
| WO-2015157483-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY, SUBSTITUTED IN POSITION 3 BY A NON-AROMATIC RING CARRYING A HALOALKYL SUBSTITUENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334946-A1 | OXOLUPENE DERIVATIVES | BET1, CYP51A1, PGGT1B | P2RX7 4134/4885MAPK1 3859/4885PSEN1 1261/4885 |
| US-20150291655-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, CYP8B1, LSS | P2RX7 3047/4885MAPK1 2233/4885PSEN1 3736/4885 |
| US-20170340650-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, CYP8B1, LSS | P2RX7 3047/4885MAPK1 2233/4885PSEN1 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.